| Description |
This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-TnC-A1 scFv to IL2. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the TnC-A1 as well as the biological activity of IL2. F16-IL2, a clinical-stage immunocytokine consisting of human interleukin (IL)-2 fused to the human antibody F16. No human anti-fusion protein antibodies (HAFA) response was detected. This immunocytokine was designed for treating metastatic breast cancer.
|